Compass Pathways plc announced that it has appointed Teri Loxam as Chief Financial Officer, effective as of the later of March 1, 2024 or the filing of the Company?s annual report for the period ending December 31, 2023 (the ?Effective Date?). She will be based in the company?s New York City office. Teri, age 51 will serve as an advisor during the period leading up to her appointment as CFO.

Teri brings to Compass deep and extensive strategic experience working for publicly traded companies, in the pharmaceutical and biotechnology sectors, and beyond. She joins the company from Gameto, where she was CFO and played a pivotal role in negotiating multiple licensing agreements and helping to develop the regulatory and commercial strategy for their lead product. Teri previously served as CFO and Chief Operating Officer of Kira Pharmaceuticals, where she advanced their lead asset into Phase 2 and grew the company?s pipeline.

As CFO of SQZ Biotech, Teri led the company to a successful IPO and raised over $200 million in her first 18 months in her role. Earlier in her career, she held senior leadership positions in investor relations and global communications at Merck and Co. and Bristol-Myers Squibb, and served as Vice President of Investor Relations at IMAX, an entertainment technology company.

Teri also serves as a member of the boards of directors and audit chair of Vaxcyte Inc. and Cardiol Therapeutics. Ms. Loxam holds an M.B.A. from the University of California, Irvine, Paul Merage School of Business, and a B.Sc. from the University of Victoria.

Mary-Rose Hughes will continue to serve as Compass?s interim CFO until the Effective Date.